

01-03-02

# UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.

J&amp;J 2084

First Inventor

Fanning, et. al.

Title

Double-Stranded RNA-Mediated Gene Suppression

Express Mail Label No.

EL710607275US

Only for new nonprovisional applications under 37 CFR 1.53(b)

## APPLICATION ELEMENTS

See MPEP Chapter 600 concerning utility patent application contents.

ADDRESS TO: Commissioner for Patents  
Box Patent Application  
Washington, DC 202311. ☒ Fee Transmittal Form (e.g., PTO/SB/17)  
(submit an original and a duplicate for fee processing)2. ☐ Applicant claims small entity status.3. ☒ Specification [Total Pages 69]

(Preferred arrangement set forth below)

- Descriptive Title of the Invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

4. ☒ Drawing(s) (35 USC 113) [Total Sheets 16]

5. Oath or Declaration [Total Pages 4]

a. ☒ Newly unexecuted (original or copy)b. ☐ Copy from a prior application (37 CFR 1.63(d))

(for continuation/divisional with Box 18 completed)

i. ☐ **DELETION OF INVENTOR(S)**

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6. ☐ Application Data Sheet. See 37 CFR 1.767. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

a. ☒ Computer Readable Form (CRF)b. ☒ Specification Sequence Listing on:i. ☐ CD-ROM or CD-R (2 copies); orii. ☒ paper (10 pages)c. ☒ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)11. ☐ English Translation Document (if applicable)12. ☐ Information Disclosure Statement

(IDS)/PTO-1449

☐ Copies of IDS Citations13. ☐ Preliminary Amendment14. ☒ Return Receipt Postcard (MPEP 503)

(Should be specifically itemized)

15. ☐ Certified Copy of Priority Document(s)

(if foreign priority is claimed)

16. ☐ Request and Certifications under 35 U.S.C. 122

(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.

17. ☐ Other18. ☐ If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:☐ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior application No.: , filed

Prior application information: Examiner Group Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 000027777 or ☐ Correspondence Address below

Name: Philip S. Johnson, Esq.

Address: Johnson &amp; Johnson

One Johnson &amp; Johnson Plaza

New Brunswick, NJ 08933-7003 USA

## 20. TELEPHONE CONTACT

Please direct all telephone calls or telefaxes to Myra H. McCormack at:

Telephone: (732) 524-6932 Fax: (732) 524-2808

## 21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME

Myra H. McCormack

Reg. No. 36,602

SIGNATURE

Myra H. McCormack

DATE

December 28, 2001

12/28/01

c9321 U.S. PTO

c9321 U.S. PTO  
10/03/01  
860550/01

12/28/01

<b>FEE TRANSMITTAL</b>	<i>Complete if Known</i>	
	Application Number	
	Filing Date	December 28, 2001
	First Named Inventor	Fanning
	Group Art Unit	
	Examiner Name	
	Attorney Docket Number	J&J 2084

JCS12 U.S. PRO  
 10/035098  
 12/28/01

## FEE CALCULATION

### CLAIMS AS FILED

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE \$740.00
TOTAL CLAIMS	66 - 20 =	46	x 18.00	\$ 828.00
INDEPENDENT CLAIMS	23 - 3 =	20	x 84.00	\$ 1680.00
MULTIPLE DEPENDENT CLAIMS	<input checked="" type="checkbox"/>	N/A	\$280.00	\$ 280.00
			TOTAL FEES	\$3528.00

## METHOD OF PAYMENT

- ☒ Please charge Deposit Account No. 10-0750/J&J2084/MHM in the amount of \$3528.00.  
Three copies of this sheet are enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/J&J2084/MHM. Three copies of this sheet are enclosed.

<b>SUBMITTED BY:</b>		<i>Complete (if applicable)</i>
Typed or Printed Name	Myra H. McCormack	Reg. No. 36,602
Signature	<i>Myra H. McCormack</i>	Deposit Account No. 10-0750/J&J2084/MHM
	Date: 12/28/01	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fanning et al

For : Double-Stranded RNA-Mediated Gene Supprssion



Express Mail Certificate

"Express Mail" mailing number: EL710607275US

Date of Deposit: December 28, 2001


I hereby certify that this complete application, including 69 specification pages, 66 claims, 9 drawings, unexecuted Declaration and Power of Attorney, and Sequence Listing with diskette, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Diane Hetzler

(Typed or printed name of person mailing paper or fee)

A handwritten signature in cursive script, appearing to read "Diane Hetzler".

(Signature of person mailing paper or fee)




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Fanning et al.  
For: Double-Stranded RNA-Mediated Gene Suppression  
Filed: herewith  
Serial No: TBD

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I hereby verify that the computer readable diskette enclosed herewith includes the same information as provided in the Sequence Listing of the subject application, and that this statement is made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

  
Myra H. McCormack  
Reg. No. 36,602

DATE: December 28, 2001